C. Moore | AMiner学者主页

1(1199) Immune Globulin Repletion for Hypogammaglobulinemia Does Not Improve Outcomes Post-Lung Transplant

L. Sacha, T. Werner,C. Moore,J. McDyer,P. Sanchez,C. Iasella

opportunistic infections in the early post-conversion period.Initiation of respective antibacterial, antiviral, and antifungal prophylaxis may be warranted.

2023JOURNAL OF HEART AND LUNG TRANSPLANTATION（2023）

引用

AI阅读

2Use of Granulocyte Colony Stimulating Factor After Lung Transplantation is Not Associated with Increased Likelihood of Acute Cellular Rejection

S. Fredrick,C. Iasella,L. Sacha,R. Rivosecchi,M. Morrell,P. Sanchez,J. Pilewski,M. Snyder,J. McDyer,C. Moore

2021AMERICAN JOURNAL OF TRANSPLANTATION（2021）

引用

AI阅读

3Idiopathic Pulmonary Fibrosis Lung Transplant Recipients Are at Increased Risk for Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder.

C. J. Iasella,S. Winters, A. Kois, J. Cho,S. J. Hannan,R. Koshy,C. Moore,E. A. Lendermon,J. Pilewski,M. Morrell,P. G. Sanchez,D. Kass,

IPF-LTRs are at increased susceptibility for PTLD compared to non-IPF LTRs. LTRs who received alemtuzumab induction were at increased risk for PTLD, particularly those who were EBV mismatches. Ongoing studies are being conducted to understand the mechanisms driving PTLD in IPF-LTRs and develop strategies to mitigate risk.

2020JOURNAL OF HEART AND LUNG TRANSPLANTATION（2020）

引用

AI阅读

4Outcomes Of A Pre-Transplant Desensitization Protocol With Carfilzomib, Plasmapheresis, And Ivig For Broadly Sensitized Lung Transplant Candidates: A Case Series